Rekombinanter EGFR (Panitumumab Biosimilar) Antikörper
Kurzübersicht für Rekombinanter EGFR (Panitumumab Biosimilar) Antikörper (ABIN7795086)
Target
Antikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Güteklasse
-
-
Expressionssystem
- Mammalian cells
-
Verwendungszweck
- Panitumumab Biosimilar, Endotoxin 0.05 EU/mg
-
Produktmerkmale
- Panitumumab, a fully anti-EGFR (epidermal growth factor receptor, EGF receptor, ErbB-1 and HER1 in humans) human monoclonal antibody, is used for the treatment of refractory EGFR-expressing metastatic colorectal cancer in patients with non-mutated (wild-type) KRAS".
-
Aufreinigung
- Protein A or G affinity column
-
Reinheit
- >95 % by reducing SDS-PAGE
-
Endotoxin-Niveau
- Less than 0.5 EU/mg of protein as determined by LAL method
-
Immunogen
- Human EGFR / ErbB-1 / HER1
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- > 3 mg/mL
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- EGFR (Panitumumab Biosimilar)
-
Andere Bezeichnung
- Panitumumab Biosimilar
-
Substanzklasse
- Biosimilar
Target
-